Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-103 is an early-stage microecological (probiotic-based) topical cream being developed by **Dalian ASIA SPACE Pharmaceutical** for the treatment of **atopic dermatitis**. As a microecological preparation, the drug is designed to modulate the skin's microbiome to restore barrier function and reduce the inflammation associated with eczema. The program is currently in preclinical development, utilizing a probiotic-based formulation to address the dysbiosis typically observed in atopic skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AS-103.